Optimization of RGD-modified nano-liposomes encapsulating eptifibatide

ABSTRACT

Background: Eptifibatide [Integrilin] is an intravenous [IV] peptide drug that selectively inhibits ligand binding to the platelet GP IIb/IIIa receptor. It is an efficient peptide drug, however has a short half-life. Therefore, antithrombotic agents like eptifibatide are required to become improved with a protected and targeted delivery system such as using nano-liposomes to the site of thrombus